Skip to main content
Verified Statutory Healthcare Resource — Indian Pharmacopoeia (IP) / CDSCO / PMBJP Jan Aushadhi Standards
Fever & Pain 6 min read • Last Updated: September 2026

Ultracet (Tramadol + Paracetamol): Uses, Habit-forming Risks & Precautions

Learn about Ultracet (Tramadol 37.5mg + Paracetamol 325mg): moderate-to-severe pain, Schedule H1 narcotic regulations, dependence precautions, and side...

Statutory Medical Disclaimer & Emergency Safety Notice The pharmacological and therapeutic data presented in this educational guide is synthesized exclusively for public health literacy, academic reference, and educational purposes in conformity with the Indian Pharmacopoeia (IP 2022) and guidelines established by the Central Drugs Standard Control Organisation (CDSCO). This content does not constitute medical diagnosis, formal physician opinion, or individualized therapeutic instruction. Under the Drugs and Cosmetics Act, 1940 and the National Medical Commission (Professional Conduct) Regulations, Schedule H, H1, and X pharmaceutical formulations must be prescribed and monitored by a registered medical practitioner (RMP). Patients must not initiate, alter, or terminate any therapeutic drug regimen without formal clinical evaluation by their treating physician or a licensed healthcare professional. For acute medical emergencies, dial 112 / 108 (India) immediately.
🩺 Quick Clinical Answer

Ultracet combines Tramadol (37.5mg, an opioid agonist) and Paracetamol (325mg) for moderate-to-severe acute pain unresponsive to plain analgesics. Because Tramadol acts on opioid receptors and inhibits serotonin reuptake, it carries risks of physical dependence, drowsiness, and nausea. It is a Schedule H1 prescription-only medicine.

1. Dual Mechanism on Pain Pathways

Tramadol binds to mu-opioid receptors in the central nervous system and blocks reuptake of norepinephrine and serotonin. Paracetamol provides complementary non-opioid analgesic activity.

2. Dependence & Withdrawal Safeguards

Ultracet should be prescribed for short durations (typically 3 to 7 days). Abrupt discontinuation after extended use can trigger withdrawal symptoms like agitation, insomnia, and sweating.

3. Schedule H1 CDSCO Mandate

In India, Tramadol combinations fall under Schedule H1, requiring chemists to record patient details, prescribing physician info, and date in a registered logbook.

PMBJP Jan Aushadhi Price Transparency

Top 8 Essential Indian Medicines: Branded MRP vs. Jan Aushadhi Generic Comparison

Compare average Indian retail MRP of top branded formulations against government-certified PMBJP Jan Aushadhi bioequivalent generic prices and active salts. Verified against official PMBJP formularies, NPPA price caps, and CDSCO regulatory registries.

Brand Name Leading Manufacturer Active Salt Formulation (IP) Branded MRP Jan Aushadhi Price Savings %
Augmentin 625 Duo GlaxoSmithKline Pharmaceuticals Amoxicillin Trihydrate 500mg + Potassium Clavulanate 125mg IP ₹220.00 ₹58.00 74%
Dolo 650 Micro Labs Ltd Paracetamol (Acetaminophen) 650mg IP ₹34.00 ₹5.50 84%
Pantocid 40 Sun Pharmaceutical Industries Pantoprazole Sodium 40mg IP (Gastro-resistant) ₹155.00 ₹8.00 95%
Azithral 500 Alembic Pharmaceuticals Azithromycin Dihydrate 500mg IP ₹132.00 ₹24.00 82%
Glycomet 500 USV Private Limited Metformin Hydrochloride 500mg IP ₹24.00 ₹4.50 81%
Shelcal 500 Torrent Pharmaceuticals Elemental Calcium 500mg + Cholecalciferol (Vit D3) 250 IU IP ₹134.00 ₹16.00 88%
Telma 40 Glenmark Pharmaceuticals Telmisartan 40mg IP ₹92.00 ₹7.50 92%
Montair-LC Cipla Ltd Montelukast Sodium 10mg + Levocetirizine Dihydrochloride 5mg IP ₹210.00 ₹18.00 91%
Combined 8-Drug Essential Therapy Basket Total: ₹1,001.00 ₹141.00 85.9% Net Savings
Additional high-volume Indian medicines bioequivalent generic savings: Atorva 10 (Atorvastatin 10mg: Branded ₹110.00 vs Jan Aushadhi ₹12.00, 89% savings), Allegra 120 (Fexofenadine 120mg: Branded ₹215.00 vs Jan Aushadhi ₹32.00, 85% savings). Official Portal: PMBJP National Formulary (janaushadhi.gov.in) →

Frequently Asked Questions (Clinical & Regulatory)

Q1: Can I drive while taking Ultracet?

No. Tramadol causes significant dizziness, sedation, and impaired psychomotor coordination.

Q2: Can Ultracet cause constipation?

Yes, opioid-induced slowing of intestinal peristalsis is a common side effect. Drink plenty of fluids and increase dietary fiber.

Q3: What is the maximum daily safe limit for Paracetamol in adults?

Under Indian Pharmacopoeia and CDSCO guidance, the absolute ceiling for adult paracetamol dosing from all sources is 4,000 mg per 24 hours (or 3,200 mg in prolonged administration). Exceeding this limit rapidly depletes hepatic glutathione and leads to toxic accumulation of N-acetyl-p-benzoquinone imine (NAPQI), resulting in acute hepatocellular necrosis.

Q4: Can Jan Aushadhi generic paracetamol be substituted for branded tablets like Dolo 650 or Calpol?

Yes. Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) paracetamol tablets contain identical Paracetamol IP at tested NABL bioequivalence standards (80–125% AUC confidence interval), delivering identical antipyretic and analgesic efficacy at ₹5.50 per strip compared to ₹34.00 for branded formulations.

Q5: Why should NSAIDs like Ibuprofen or Diclofenac be avoided during suspected dengue fever?

In undiagnosed acute febrile illnesses, particularly dengue fever, NSAIDs impair platelet aggregation and cause gastric mucosal erosions, sharply elevating the risk of severe internal gastrointestinal hemorrhage and dengue hemorrhagic syndrome. Paracetamol remains the only safe first-line antipyretic.

MediMatch AI Clinical Pharmacology Review Board
Clinically reviewed by Dr. Vikram Anand, MBBS, MD (Clinical Pharmacology), Dr. Aditi Sharma, MD Pharmacology & Dr. Rajesh Nair, PharmD, RPh

This clinical guide is authored and reviewed in accordance with the regulatory standards of the Indian Pharmacopoeia (IP), Central Drugs Standard Control Organization (CDSCO) drug schedules, and Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) bioequivalence guidelines. All therapeutic recommendations and drug interaction warnings are cross-referenced with official statutory publications.

Official Statutory References: Indian Pharmacopoeia Commission (ipc.gov.in) → PMBJP Jan Aushadhi Portal (janaushadhi.gov.in) → CDSCO Health & Family Welfare (cdsco.gov.in) →
Digital Personal Data Protection (DPDP) Act, 2023 Statutory Health Privacy Disclosure

Under India's Digital Personal Data Protection (DPDP) Act, 2023, MediMatch AI functions as a data fiduciary committed to zero retention of private health identifiers. Browsing educational guides, reviewing active salt monographs, and executing search queries occur without tracking or commercial profiling. All client interactions with prescription readers or lab decoders execute ephemerally in volatile memory with zero server-side storage of protected health information (PHI). For inquiries regarding data fiduciary obligations, contact our Data Protection Officer at privacy@medimatchai.in.